Quick Answer
Taysha Gene Therapies, Inc. reported Net Income of -$109.00 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$109.00M | -22.1% |
| 2024 | -$89.30M | +20.0% |
| 2023 | -$111.57M | +32.8% |
| 2022 | -$166.01M | +4.9% |
| 2021 | -$174.52M | -190.8% |
| 2020 | -$60.01M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$32.73M | -28.2% | -21.8% |
| June 30, 2025 | -$26.88M | -28.4% | -24.9% |
| March 31, 2025 | -$21.53M | +10.5% | +15.7% |
| September 30, 2024 | -$25.52M | +78.2% | -22.0% |
| June 30, 2024 | -$20.93M | +14.9% | +13.0% |
| March 31, 2024 | -$24.06M | -36.5% | +79.5% |
| September 30, 2023 | -$117.09M | -341.4% | -376.0% |
| June 30, 2023 | -$24.60M | +27.8% | -39.6% |
- Taysha Gene Therapies, Inc. showed a decrease of -22.1% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Taysha Gene Therapies, Inc.’s net income has declined by 81.6% (from -$60.01 million to -$109.00 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: